Ardiovasc Diabetol:TyG指数与亚临床动脉粥样硬化相关性的性别差异

2021-10-18 从医路漫漫 MedSci原创

胰岛素抵抗(IR)是非糖尿病患者心血管疾病(CVD)的已知危险因素,其与高血糖或相关代谢因素有关。甘油三酯-葡萄糖(TYG)指数是通过血清葡萄糖和胰岛素浓度来定义的,认为是胰岛素抵抗的替代标记物

背景:胰岛素抵抗(IR)是非糖尿病患者心血管疾病(CVD)的已知危险因素,其与高血糖或相关代谢因素有关。甘油三酯-葡萄糖(TYG)指数是通过血清葡萄糖和胰岛素浓度来定义的,认为是胰岛素抵抗的替代标记物。

目的:本研究旨在探讨不同性别的TYG指数与亚临床动脉粥样硬化(SA)早期的关系。

方法:I-Lan纵向老龄化研究(ILAS)招募了1457名年龄在50-80岁的受试者。每名受试者均获得人口学数据和TYG指数{ln[空腹甘油三酯(mg/dL)×空腹血糖(mg/dL)]/2}。根据性别和TYG指数的第50个百分位数(≥8.55或<8.55)对患者进行进一步分层。SA定义为整个队列第75百分位数的平均颈动脉内膜-中层厚度(CIMT)。比较两组间的影像特征和SA的存在情况。用Logistic回归分析TYG指数与SA的关系。

结果:TYG指数高(≥8.55)的患者有较高的体重指数、患高血压和糖尿病的风险。与TYG指数较低的人(<8.55)相比,他们的血脂水平较高,包括总胆固醇(T-Chol)和低密度脂蛋白(LDL)。在非糖尿病女性中观察到性别差异,高TyG指数组的SA患病率明显高于低TyG指数组。在多因素Logistic回归分析中,调整传统危险因素[调整后的优势比(OR):1.510,95%CI为1.010~2.257,p=0.045]后,非糖尿病女性的高TYG指数与SA独立相关,而在非糖尿病男性中无统计学意义。TYG指数与糖尿病患者中SA的存在无关,与性别无关。

图1 TyG指数与cIMT的相关系数。黑色*表示p值< 0.001。红色*表示p值< 0.05。BMI体重指数、DM糖尿病、CKD慢性肾病、HDL高密度脂蛋白、LDL低密度脂蛋白、HbA1c血红蛋白A1c、hs-CRP高敏C反应蛋白、eGFR估计肾小球滤过率、cIMT颈动脉内膜-中膜厚度

表 非DM患者中cIMT≥0.75 mm(第75个百分点)发生率相关因素的单因素和多因素logistic回归分析(n = 1255)

图2 全人群和非DM组的性别差异。aOR调整优势比,调整变量:年龄,BMI, HTN, CKD, UA, hsCRP

结论:在非糖尿病患者中,高TYG指数与SA和性别差异显著相关。这一结果可能突出了针对性别的风险管理策略的必要性,以预防动脉粥样硬化。

原文出处:

  Lu YW,  Chang CC,  Chou RH,et al.Gender difference in the association between TyG index and subclinical atherosclerosis: results from the I-Lan Longitudinal Aging Study.Cardiovasc Diabetol 2021 Oct 13;20(1)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1639912, encodeId=1166163991231, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 11 15:29:49 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947237, encodeId=65c9194e237e0, content=<a href='/topic/show?id=6e2c1e982f9' target=_blank style='color:#2F92EE;'>#TyG指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17982, encryptionId=6e2c1e982f9, topicName=TyG指数)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Tue May 17 06:29:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761717, encodeId=efaf1e617176f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun May 01 16:29:49 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939258, encodeId=296e193925872, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Nov 06 11:29:49 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735817, encodeId=de2e1e3581774, content=<a href='/topic/show?id=cc4e2420687' target=_blank style='color:#2F92EE;'>#亚临床动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24206, encryptionId=cc4e2420687, topicName=亚临床动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1433999553, createdName=zhangbaojun, createdTime=Sun Feb 20 10:29:49 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837993, encodeId=d8bc183e99351, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 15 19:29:49 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944718, encodeId=6fed1944e18c4, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Jul 02 13:29:49 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061557, encodeId=4453106155e54, content=<a href='/topic/show?id=98773329350' target=_blank style='color:#2F92EE;'>#动脉粥样硬化#</a>亚临床更应关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33293, encryptionId=98773329350, topicName=动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Mon Oct 18 18:10:08 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1639912, encodeId=1166163991231, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 11 15:29:49 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947237, encodeId=65c9194e237e0, content=<a href='/topic/show?id=6e2c1e982f9' target=_blank style='color:#2F92EE;'>#TyG指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17982, encryptionId=6e2c1e982f9, topicName=TyG指数)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Tue May 17 06:29:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761717, encodeId=efaf1e617176f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun May 01 16:29:49 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939258, encodeId=296e193925872, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Nov 06 11:29:49 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735817, encodeId=de2e1e3581774, content=<a href='/topic/show?id=cc4e2420687' target=_blank style='color:#2F92EE;'>#亚临床动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24206, encryptionId=cc4e2420687, topicName=亚临床动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1433999553, createdName=zhangbaojun, createdTime=Sun Feb 20 10:29:49 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837993, encodeId=d8bc183e99351, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 15 19:29:49 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944718, encodeId=6fed1944e18c4, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Jul 02 13:29:49 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061557, encodeId=4453106155e54, content=<a href='/topic/show?id=98773329350' target=_blank style='color:#2F92EE;'>#动脉粥样硬化#</a>亚临床更应关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33293, encryptionId=98773329350, topicName=动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Mon Oct 18 18:10:08 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1639912, encodeId=1166163991231, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 11 15:29:49 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947237, encodeId=65c9194e237e0, content=<a href='/topic/show?id=6e2c1e982f9' target=_blank style='color:#2F92EE;'>#TyG指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17982, encryptionId=6e2c1e982f9, topicName=TyG指数)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Tue May 17 06:29:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761717, encodeId=efaf1e617176f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun May 01 16:29:49 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939258, encodeId=296e193925872, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Nov 06 11:29:49 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735817, encodeId=de2e1e3581774, content=<a href='/topic/show?id=cc4e2420687' target=_blank style='color:#2F92EE;'>#亚临床动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24206, encryptionId=cc4e2420687, topicName=亚临床动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1433999553, createdName=zhangbaojun, createdTime=Sun Feb 20 10:29:49 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837993, encodeId=d8bc183e99351, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 15 19:29:49 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944718, encodeId=6fed1944e18c4, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Jul 02 13:29:49 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061557, encodeId=4453106155e54, content=<a href='/topic/show?id=98773329350' target=_blank style='color:#2F92EE;'>#动脉粥样硬化#</a>亚临床更应关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33293, encryptionId=98773329350, topicName=动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Mon Oct 18 18:10:08 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1639912, encodeId=1166163991231, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 11 15:29:49 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947237, encodeId=65c9194e237e0, content=<a href='/topic/show?id=6e2c1e982f9' target=_blank style='color:#2F92EE;'>#TyG指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17982, encryptionId=6e2c1e982f9, topicName=TyG指数)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Tue May 17 06:29:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761717, encodeId=efaf1e617176f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun May 01 16:29:49 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939258, encodeId=296e193925872, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Nov 06 11:29:49 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735817, encodeId=de2e1e3581774, content=<a href='/topic/show?id=cc4e2420687' target=_blank style='color:#2F92EE;'>#亚临床动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24206, encryptionId=cc4e2420687, topicName=亚临床动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1433999553, createdName=zhangbaojun, createdTime=Sun Feb 20 10:29:49 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837993, encodeId=d8bc183e99351, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 15 19:29:49 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944718, encodeId=6fed1944e18c4, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Jul 02 13:29:49 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061557, encodeId=4453106155e54, content=<a href='/topic/show?id=98773329350' target=_blank style='color:#2F92EE;'>#动脉粥样硬化#</a>亚临床更应关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33293, encryptionId=98773329350, topicName=动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Mon Oct 18 18:10:08 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
    2021-11-06 quxin068
  5. [GetPortalCommentsPageByObjectIdResponse(id=1639912, encodeId=1166163991231, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 11 15:29:49 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947237, encodeId=65c9194e237e0, content=<a href='/topic/show?id=6e2c1e982f9' target=_blank style='color:#2F92EE;'>#TyG指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17982, encryptionId=6e2c1e982f9, topicName=TyG指数)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Tue May 17 06:29:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761717, encodeId=efaf1e617176f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun May 01 16:29:49 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939258, encodeId=296e193925872, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Nov 06 11:29:49 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735817, encodeId=de2e1e3581774, content=<a href='/topic/show?id=cc4e2420687' target=_blank style='color:#2F92EE;'>#亚临床动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24206, encryptionId=cc4e2420687, topicName=亚临床动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1433999553, createdName=zhangbaojun, createdTime=Sun Feb 20 10:29:49 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837993, encodeId=d8bc183e99351, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 15 19:29:49 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944718, encodeId=6fed1944e18c4, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Jul 02 13:29:49 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061557, encodeId=4453106155e54, content=<a href='/topic/show?id=98773329350' target=_blank style='color:#2F92EE;'>#动脉粥样硬化#</a>亚临床更应关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33293, encryptionId=98773329350, topicName=动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Mon Oct 18 18:10:08 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1639912, encodeId=1166163991231, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 11 15:29:49 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947237, encodeId=65c9194e237e0, content=<a href='/topic/show?id=6e2c1e982f9' target=_blank style='color:#2F92EE;'>#TyG指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17982, encryptionId=6e2c1e982f9, topicName=TyG指数)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Tue May 17 06:29:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761717, encodeId=efaf1e617176f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun May 01 16:29:49 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939258, encodeId=296e193925872, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Nov 06 11:29:49 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735817, encodeId=de2e1e3581774, content=<a href='/topic/show?id=cc4e2420687' target=_blank style='color:#2F92EE;'>#亚临床动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24206, encryptionId=cc4e2420687, topicName=亚临床动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1433999553, createdName=zhangbaojun, createdTime=Sun Feb 20 10:29:49 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837993, encodeId=d8bc183e99351, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 15 19:29:49 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944718, encodeId=6fed1944e18c4, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Jul 02 13:29:49 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061557, encodeId=4453106155e54, content=<a href='/topic/show?id=98773329350' target=_blank style='color:#2F92EE;'>#动脉粥样硬化#</a>亚临床更应关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33293, encryptionId=98773329350, topicName=动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Mon Oct 18 18:10:08 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1639912, encodeId=1166163991231, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 11 15:29:49 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947237, encodeId=65c9194e237e0, content=<a href='/topic/show?id=6e2c1e982f9' target=_blank style='color:#2F92EE;'>#TyG指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17982, encryptionId=6e2c1e982f9, topicName=TyG指数)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Tue May 17 06:29:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761717, encodeId=efaf1e617176f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun May 01 16:29:49 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939258, encodeId=296e193925872, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Nov 06 11:29:49 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735817, encodeId=de2e1e3581774, content=<a href='/topic/show?id=cc4e2420687' target=_blank style='color:#2F92EE;'>#亚临床动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24206, encryptionId=cc4e2420687, topicName=亚临床动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1433999553, createdName=zhangbaojun, createdTime=Sun Feb 20 10:29:49 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837993, encodeId=d8bc183e99351, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 15 19:29:49 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944718, encodeId=6fed1944e18c4, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Jul 02 13:29:49 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061557, encodeId=4453106155e54, content=<a href='/topic/show?id=98773329350' target=_blank style='color:#2F92EE;'>#动脉粥样硬化#</a>亚临床更应关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33293, encryptionId=98773329350, topicName=动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Mon Oct 18 18:10:08 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1639912, encodeId=1166163991231, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 11 15:29:49 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947237, encodeId=65c9194e237e0, content=<a href='/topic/show?id=6e2c1e982f9' target=_blank style='color:#2F92EE;'>#TyG指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17982, encryptionId=6e2c1e982f9, topicName=TyG指数)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Tue May 17 06:29:49 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761717, encodeId=efaf1e617176f, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun May 01 16:29:49 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939258, encodeId=296e193925872, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Nov 06 11:29:49 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735817, encodeId=de2e1e3581774, content=<a href='/topic/show?id=cc4e2420687' target=_blank style='color:#2F92EE;'>#亚临床动脉粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24206, encryptionId=cc4e2420687, topicName=亚临床动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1433999553, createdName=zhangbaojun, createdTime=Sun Feb 20 10:29:49 CST 2022, time=2022-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837993, encodeId=d8bc183e99351, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 15 19:29:49 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944718, encodeId=6fed1944e18c4, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Jul 02 13:29:49 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061557, encodeId=4453106155e54, content=<a href='/topic/show?id=98773329350' target=_blank style='color:#2F92EE;'>#动脉粥样硬化#</a>亚临床更应关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33293, encryptionId=98773329350, topicName=动脉粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Mon Oct 18 18:10:08 CST 2021, time=2021-10-18, status=1, ipAttribution=)]
    2021-10-18 医者仁者

    #动脉粥样硬化#亚临床更应关注

    0

相关资讯

JAMA Cardiol:他汀类药物治疗与冠脉粥样硬化斑块进展的关系

他汀类药物的使用与冠状动脉粥样硬化向高密度钙转化的发生率更高有关

JCH:21年研究!夜间脉压高,心血管死亡风险增加160%,全因死亡风险增加72%

脉压=收缩压-舒张压,可作为衡量动脉粥样硬化程度的指标之一。脉压随年龄的增长而增加,过高的脉压值,更是心血管事件和全因死亡风险的独立危险因素,尤其是在中老年人群中。

北京大学孔炜团队发现细胞外基质Nidogen-2 维持血管平滑肌细胞收缩表型并抑制血管损伤后新生内膜形成

首次发现基底膜蛋白Nidogen-2通过调控Jagged1-Notch3信号以维持血管平滑肌细胞收缩表型并抑制血管损伤后再狭窄,具有重要的理论意义。

牛津大学:超140万人的研究显示,食用红肉和加工肉类或与心脏病风险增加有关

未加工的红肉和加工肉每天食用高出50克,分别与9%和18%的IHD风险有关;没有证据表明IHD风险与食用家禽肉有关。

Clinical Nutrition:怀孕期间维生素 B12、叶酸和同型半胱氨酸的浓度与儿童学龄期动脉粥样硬化的早期迹象的关系

动脉粥样硬化和相关的心血管疾病似乎至少部分起源于生命的最早阶段。尸检研究表明,内膜增厚和脂肪条纹的形成都与动脉粥样硬化的发病机制有关。

Hypertension:动脉硬化、动脉粥样硬化和心血管健康与心血管疾病发病率的关系

该研究的结果表明,同时伴有动脉粥样硬化、动脉硬化和心血管健康状况不佳会大大增加心血管疾病的风险,而它们的缺失则表明风险较低。